Development and feasibility of randomized trial to reduce urinary bisphenols in women with obesity

Pilot and Feasibility Studies

卷:7

Suzanne Phelan¹  Alyssa Bird¹  Megan Guy¹  Zoe Delli-Bovi¹  Todd Hagobian¹  Adrian Mercado¹ 

[1] Center for Health Research and Department of Kinesiology and Public Health, California Polytechnic State University;

关键词: Bisphenol A;    Body weight;    Diet;    Endocrine disruptors;   

DOI  :  10.1186/s40814-020-00744-5

来源: DOAJ

【 摘 要 】

Abstract Background Bisphenol exposure is widespread and correlated with diabetes and cardiovascular disease. Previous intervention studies have successfully lowered bisphenol exposure among women of normal weight. The primary objective of this study was to develop and test the feasibility of a 3-week behavioral change intervention, rooted in social cognitive theory, to lower a broad range of bisphenols (BPA, BPS, and BPF) in women with obesity. Methods Thirty women with obesity (31.1 ± 5.6 kg/m2, 21.1 ± 3.1 years) were randomly assigned to an intervention or control. The intervention included weekly face-to-face meetings to reduce bisphenol exposures from food, cosmetics, and packaged products. Fasting urinary bisphenols, creatinine, and weight were assessed at study entry and after 3 weeks. Results The intervention was evaluated as feasible (100% of enrollment and recruitment, 96% of retention and attendance at lesson plan visits, and 96% of a collection of urine samples). Adherence to the intervention was estimated based on completion of self-monitoring records; the number of daily records completed was 7.7 ± 1.3 (mean ± SD) after week 1, 7.1 ± 1.5 after week 2, and 4.4 ± 0.9 after week 3. In secondary analysis, there was a significant treatment × time effect on creatinine-corrected urinary BPS (− 1.42 μg/g creatinine in the intervention vs. − 0.09 μg/g creatinine in the control group). Conclusion In women with obesity, the 3-week intervention was considered feasible with promising preliminary results of decreasing BPS concentrations. These data warrant future large-scale clinical trial interventions to reduce bisphenol exposure and determine whether reductions in bisphenols positively impact diabetes and cardiovascular disease risk markers. This study was retroactively registered at ClinicalTrial.gov Identifier NCT03440307.

【 授权许可】

Unknown